Meropenem: A pharmacoeconomic review of its use in serious infections

PharmacoEconomics

Volumn 13, Issue 3, 1998, Pages 359-377

  Holliday, Stephen M ^a   Benfield, Paul ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; INFECTION; PRIORITY JOURNAL; REVIEW;

BACTERIAL INFECTIONS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; THIENAMYCINS;

EID: 0031891845     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199813030-00010     Document Type: Review

References (94)

1. Col NF, O'Connor RW. Estimating worldwide current antibiotic usage: report of Task Force 1. Rev Infect Dis 1987; 9 Suppl. 3: S232-43
2. Barriere SL. Cost-containment of antimicrobial therapy. Drug Intell Clin Pharm 1985; 19: 278-81
3. Meropenem: a new parenteral broad-spectrum antibiotic. Med Lett Drugs Ther 1996 Sep 27; 38 (984): 88-90
4. British National Formulary. BNF. March ed. London: British Medical Association and The Pharmaceutical Press, 1997
5. Balinsky W, Nesbitt S. Cost-effectiveness of outpatient parenteral antibiotics: a review of the literature. Am J Med 1989; 87: 301-5
6. U.S. Bureau of the Census. Statistical abstract of the United States. 113th ed. Washington, D.C.: US Department of Commerce
7. Milkovich G. Benefits of outpatient parenteral antibiotic therapy: to the individual, the institution, third-party payers and society. Int J Antimicrob Agents 1995; 5: 27-31
8. Williams DN. Home intravenous antibiotic therapy (HIVAT): indications, patients and antimicrobial agents. Int J Antimicrob Agents 1995; 5: 3-8
9. Eisenberg JM, Kitz DS. Savings from outpatient antibiotic therapy for osteomyelitis: economic analysis of a therapuetic strategy. JAMA 1986; 255: 1584-91
10. Williams DN. Reducing costs and hospital stay for pneumonia with home intravenous cetotaxime treatment: results with a computerized ambulatory drug delivery system. Am J Med 1994 Aug 15; 97 Suppl. 2A: 50-5
11. Grizzard MB, Harris G, Karns H. Use of outpatient parenteral antibiotic therapy in a health maintenance organization. Rev Infect Dis 1991; 13 Suppl. 2: S174-9
12. Kerr JR, Barr JG, Smyth ETM, et al. Technique for the calculation of the true costs of antibiotic therapy. Eur J Clin Microbiol Infect Dis 1992; 11: 823-7
13. Smyth ETM, Barr JG, Hogg GM. Hidden costs of antibiotics. Pharmacoeconomics 1996 Jul; 10 (1): 99-100
14. Hotchkies RN, Grima T, Hedayati S. The total process cost of parenteral antibiotic therapy: beyond drug acquisition cost. Clin Ther 1996; 18 (4): 716-25
15. Plumridge RJ. Cost comparison of intravenous antibiotic administration. Med J Aust 1990; 153: 516-8
16. Garrelts JC, Smith DF, Ast ID, et al. A comparison of the safety, timing and cost-effectiveness of administering antibiotics by intravenous bolus (push) versus intravenous piggback (slow infusion) in surgical prophylaxis. Pharmacoeconomics 1992; 1: 116-23
17. Kaplan JM, Goretski SA, Kieth S, et al. Cost of antibiotic therapy for infants and children. Pediatr Infect Dis J 1990; 9: 722-8
18. Smyth ETM, Barr JG, Hogg GM. An assessment of hidden costs on total prescribing costs of courses of meropenem and imipenem/cilastatin. Br J Med Econ 1996; 10: 325-40
19. Davey P, Dodd T, Kerr S, et al. Audit of IV antibiotic administration. Pharm J 1990; 30: 793-6
20. Newhouse JG, Paul VM, Waugh NA, et al. Reducing IV waste to under 2.25 percent. Hosp Pharm 1988; 23: 241-7
21. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study. N Engl J Med 1991; 324: 377-84
22. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs and attributable mortality. JAMA 1997; 277: 301-6
23. Meyer RD. Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides. Am J Med 1986; 80 Suppl. 6b: 119-26
24. Gatell JM, Ferran F, Araujo V, et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 1987; 31: 1383-7
25. Mathews A, Bailie GR. Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services. J Clin Pharm Ther 1987; 12: 273-91
26. Holloway JJ, Smith CR, Moore RD, et al. Comparative cost-effectiveness of gentamycin and tobramycin. Ann Intern Med 1984; 101: 764-9
27. Eisenberg JM, Koffer H, Glick HA, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987; 107: 900-9
28. Davey P, Hernanz C, Lynch W, et al. Human and non-financial costs of hospital-acquired infection. J Hosp Infect 1991; 18 Suppl. A: 79-84
29. O'Hanley P, Easaw J, Rugo H, et al. Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. Am J Med 1989; 87: 605-13
30. Rodvold KA, Danziger LH, Ouinn JP. Single daily doses of aminoglycosides. Lancet 1997 Nov 15; 350: 1412
31. Shlaes DM, Gerding DN, John Jr JF, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance. Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584-99
32. Carmeli Y, Troillet N, Karchmer A, et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa (PA) [abstract]. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sep 28-Oct 1: Toronto. Washington, D.C.: American Society for Microbiology, 1997: 375
33. Davey PG, Malek MM, Parker SE. Pharmacoeconomics of antibacterial treatment. Pharmacoeconomics 1992; 1: 409-37
34. Hessen MT, Kaye D. Nosocomial pneumonia. Crit Care Clin 1988; 4: 245-57
35. Coast J, Smith RD, Millar MR. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Econ 1996; 5: 217-26
36. Wiseman LR, Wagstaff AJ, Brogden RN, et al. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995 Jul; 50: 73-101
37. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 1-17
38. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996 Jan; 51: 99-136
39. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard: fourth ed. v. NCCLS document M7-A4 (ISBN 1-56238-309-4). 940 West Valley Road, Suite 1400. Wayne, Pennsylvania 19087: NCCLS, 1997
40. Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,245 aerobic and anaerobic pathogens isolated world wide. Diagn Microbiol Infect Dis 1997; 28: 157-63
41. Edwards JR, Turner PJ. Laboratory data which differentiate meropenem and imipenem. Scand J Infect Dis 1995 Suppl. 96: 5-10
42. Howe RA, Wilson MP, Walsh TR, et al. Susceptibility testing of Stenotrophomonas maltophilia to carbapenems. J Antimicrob Chemother 1997; 40: 13-7
43. Fish DN, Singletary TJ. Meropenem: a new carbapenem antibiotic. Pharmacotherapy 1997; 17 (4): 644-69
44. Livermore DM, Are all β-lactams created equal? Scand J Infect Dis 1996 Suppl. 101: 33-43
45. Livingstone D, Gill MJ, Wise R. Mechanisms of resistance to the carbapenems. J Antimicrob Chemother 1995; 35: 1-5
46. Livermore DM. Bacterial resistance to carbapenems. Adv Exp Med Biol 1995; 390: 25-47
47. Livermore DM. Carbapenemases. J Antimicrob Chemother 1992; 29: 609-16
48. Livermore DM. Interplay of impermeability and chromosomal β-lactamase activity of imipenem resistant P. aeruginosa. Antimicrob Agents Chemother 1992; 36: 2046-8
49. Zhou XY, Kitzis M-D, Gutmann L. Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 1387-9
50. Nilsson-Ehle I, Hutchison M, Haworth SJ, et al. Pharmacokinetics of meropenem compared to imipenem-cilaslatin in young, healthy males. Eur J Clin Microbiol Infect Dis 1991; 10: 85-8
51. Ragnar Norrby S, Faulkner KL, Newell PA. Differentiating meropenem and imipenem/cilastatin. Infect Dis Clin Pract 1997; 6: 291-303
52. Kelly HC, Hutchison M, Haworth SJ. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 35-41
53. Jones HK, Kelly HC, Hutchison M, et al. A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes. Eur J Drug Metab Pharmacokinet 1997; 22 (3): 193-9
54. Hutchison M, Faulkner KL, Turner PJ, et al. A compilation of meropenem tissue distribution data. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 43-56
55. Behre G, Schiel X, Link H, et al. Meropenem - monotherapy vs ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients [abstract]. Onkologie 1995 Oct; 18 Suppl. 2: 196
56. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996 May; 40: 1108-15
57. Shah PM, Heller A, Fuhr H-G, et al. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. Infection 1996 Nov-Dec; 24: 480-4
58. Meropenem Study Group of Leuven London Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995; 36: 185-200
59. Data on file, Zeneca Pharmaceuticals
60. Berne TV, Yellin AE, Appleman MD, et al. Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis [in English]. J Am Coll Surg 1996 May; 182: 403-7
61. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1995 Jan; 35: 139-48
62. Condon RE, Walker AP, Sirinek KR, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995 Sep; 21: 544-50
63. Geroulanos SJ. Meropenem Study Group. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 191-205
64. Huizinga WK, Warren BL, Baker LW, et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995 Jul; 36 Suppl A: 179-89
65. Kempf P, Bauernfeind A, Müller A, et al. Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections. Infection 1996 Nov-Dec; 24: 473-9
66. Kanellakopoulou K, Giamarellou H, Papadothomakos P, et al. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 1993; 12: 449-53
67. Wilson SE. Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections. Clin Infect Dis 1997 Feb; 24 Suppl. 2: S197-206
68. Colardyn F, Faulkner KL. Meropenem Serious Infection Study Group. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother 1996 Sep; 38: 523-37
69. Mouton YJ, Beuscart C. Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 145-56
70. Hamacher J, Vogel F, Lichey J, et al. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients. A comparison of nicropenem and imipenem/cilastatin. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 121-33
71. Romanelli G, Cravarezza P. Italian IMSG. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 109-19
72. Rizzato G, Magliano E, Morandini G. Efficacy of meropenem vs imipenem/cilastatin in community acquired lower respiratory tract infections (LRTI) [abstract]. Can J Infect Dis 1995 Jul; 6 Suppl. C: 240C
73. Sieger B, Berman SJ, Geckler RW, et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin. A randomized study. Crit Care Med 1997; 25 (10): 1663-9
74. Romanelli G, Cravarezza P, Ragni G, et al. Meropenem IV in lower respiratory tract infections. A multicentre comparison [in Italian]. Farmaci e Terapia 1995; 12: 1-9
75. Berman SJ, Sieger B, Geckler RW, et al. A comparative study of meropenem and ceftazidime in the treatment of patients hospitalized with community-acquired pneumonia. Curr Ther Res 1997; 58 (12): 903-16
76. Schmutzhard E, Williams KJ, Vukmirovits G, et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 85-97
77. Feris J, Rodriguez W, Puig J, et al. Meropenem (MER) vs cefotaxime (CEF) therapy (Rx) for pediatric meningitis (PM), therapeutic, pharmacologic, and epidemiologic observations [abstract]. 35th Int Conf Antimicro Ag Chemother 1995 Sep 17: 340
78. Klugman KP, Dagan R, Meropenem Meningitis Study Group. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis, Antimicrob Agents Chemother 1995 May; 39: 1140-6
79. Solberg CO, Sjursen H. Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 157-66
80. Menzin J, Huse DM, Richner R. Economic evaluation of oral ofloxacin versus standard parenteral therapy in the treatment of pneumonia. Pharmacoeconomics 1992 Aug; 2: 171-7
81. Wong VK, Wright HT, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991; 10: 122-5
82. American Hospital Formulary Service (AHFS). Imipenem and cilastin sodium. In: AHES drug information. Bethesda: American Society of Health-System Pharmacists, 1997: 207-16
83. Norrby SR, Newell PA, Fulkner KL, et al. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 207-23
84. Del Favero A. Clinically important aspects of carbapenem safety. Curr Opin Infect Dis 1994; 7 Suppl. 1: S38-42
85. Wang C, Calandra GB, Aziz MA, et al. Efficacy and safety of imipenem/cilastatin: a review of world-wide clinical experience. Rev Infect Dis 1985; 7 Suppl. 3: 528S-36S
86. Bradley JS, Faulkner KL, Klugman KP. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatr Infect Dis J 1996 Aug; 15: 749-57
87. Association of the British Pharmaceutical Industry (ABPI). Meropenem. In: ABPI compendium of data sheets and summaries of product characteristics 1996-97. London: Data-pharm Publications Limited, 1997: 1291-3
88. Hogg GM, Smith ETM, Barr JG. Prescribing costs of a new carbapenem, meropenem, in comparison with imipenem/cilastatin and ceftazidime /metronidazole. 7th Eur Congr Clin Microbiol Infect Dis 1995: 134
89. Plumridge RJ. Cost analysis of infusion versus injection delivery of imipenem/cilastatin and meropenem. Clin Drug Invest 1997 Aug; 14 (2): 132-6
90. Marquina MC, Giráldez J, Idoate A. The pharmacoeconomics of meropenem versus imipenem/cilastatin [in Spanish]. Enferm Infecc Microbiol Clin 1997 Sep; 15 Suppl. 1: 45-50
91. Bonal de Falgàs J, Pérez Botelho JM, Bravo José P. Estudio farmacoeconomico comparativo meropenem/imipenem. Diseño del estudio [in Spanish]. Revista Espanola de Farmacoeconomia. In press
92. Kilburg A, Bachinger A, Rychlik R. Medical and economic relevance of inpatient treatment of pneumonia with ceftriaxone in comparison to ciprofloxacine, meropenem and piperacillin/tazobactam [abstract]. Am J Manage Care 1997 Mar; 3 Suppl.: S57
93. Association of the British Pharmaceutical Industry (ABPI). Primaxin. In: ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1996-97. London: Data-pharm Publications Limited, 1997: 624-6
94. Marsh PK, Tice AD, Craven PC, et al. Imipenem/cilastatin therapy in the management of infections in the outpatient setting. Infect Dis Clin Pract 1996; 5(8): 498-501